Have questions? Call for answers.
See Tatum’s inspiring story from diagnosis of autosomal recessive CGD to treatment with ACTIMMUNE® (Interferon gamma-1b).
Autosomal recessive CGD carries a high risk for serious infection and mortality.
ACTIMMUNE® delivered efficacy across various patient types, including autosomal recessive patients.†,8,9
*Serious infection is defined as a clinical event requiring hospitalization and intravenous antibiotics.
†Most patients in the clinical study also received prophylactic antibiotics.
References: 1. Noack D, Rae J, Cross AR, et al. Autosomal recessive chronic granulomatous disease caused by defects in NCF-1, the gene encoding the phagocyte p47-phox: mutations not arising in the NCF-1 pseudogenes. Blood. 2001;97(1):305-311. 2. Holland SM. Chronic granulomatous disease. Hematol Oncol Clin North Am. 2013;27(1):89-99. 3. Leiding JW, Holland SM. Chronic granulomatous disease. In: Pagon RA, ed. GeneReviews. Seattle, WA: University of Washington, Seattle; 1993-2016. 4. Kuhns DB, Alvord WG, Heller T, et al. Residual NADPH oxidase and survival in chronic granulomatous disease. N Engl J Med. 2010;363(27):2600-2610. 5. Arnold DE, Heimall JR. A review of chronic granulomatous disease. Adv Ther. 2017;34(12): 2543-2557. 6. Siddiqui S, Anderson VL, Hilligoss DM, et al. Fulminant mulch pneumonitis: an emergency presentation of chronic granulomatous disease. Clin Infect Dis. 2007;45(6):673-681. 7. ACTIMMUNE® (Interferon gamma-1b) [prescribing information] Horizon. 8. The International Chronic Granulomatous Disease Cooperative Study Group. A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. N Engl J Med. 1991;324(8):509-516. 9. ACTIMMUNE® (Interferon gamma-1b) [prescribing information] Horizon.
ACTIMMUNE® (Interferon gamma-1b) is indicated:
ACTIMMUNE® (Interferon gamma-1b) is indicated: